<DOC>
	<DOCNO>NCT01720563</DOCNO>
	<brief_summary>Eighty 90 % SCCHN ( squamous cell carcinoma head neck ) patient Taiwan betel quid chewer . Thirty 40 % experienced mucositis World Health Organization ( WHO ) grade 3 cisplatin/flurouracil ( FU ) neoadjuvant chemotherapy setting . This high 8-11 % report Western population related oral submucous fibrosis betel quid chewing.Severer toxicity , esp . mucositis , could anticipate patient betel quid chewing treat concurrent chemoradiotherapy ( CCRT ) cisplatin/FU.PG2 Injection prove safe clinical use effective stimulating recovery hematopoiesis immunity chemotherapy-induced myelosuppression . It also improve Quality Life , especially fatigue , among advanced cancer patient . This study investigate effect PG2 Injection relieve adverse event concurrent chemoradiotherapy , fatigue , myelosuppression , mucositis , body weight loss , even compliance radiotherapy chemotherapy treatment patient advance pharyngeal laryngeal SCCHN .</brief_summary>
	<brief_title>A Phase II Trial PG2 Patients With Advanced Pharyngeal Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>Histological confirmation squamous cell carcinoma Primary tumor site head neck area Stage III IV disease Measurable locoregional disease distant metastasis No prior cancer treatment 2070 year old KPS â‰§ 70 Adequate bone marrow , liver , renal function Fed gastric tube without intestinal malabsorption obstruction Not pregnancy use reliable contraceptive method study Signed informed consent Willing able complete quality life questionnaire Decompensated liver function Serious concomitant illness might aggravate chemotherapy Active cardiac disease precede entry study Severe uncontrolled hypertension Uncontrolled infection History malignancy Pregnant breast feed Receiving concomitant chemotherapy , radiotherapy anticancer treatment Mental status suitable clinical trial Intestinal obstruction malabsorption .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Cancer-related fatigue</keyword>
	<keyword>astragalus polysaccharide</keyword>
	<keyword>concurrent chemoradiotherapy</keyword>
	<keyword>squamous cell carcinoma head neck</keyword>
</DOC>